On 18 July Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2014.
Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, at 12:30 p.m. CET (06:30 a.m. EDT). The event will be hosted by Sobi's CEO and President, Dr. Geoffrey McDonough. The presentation will be held in English.
The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on our website prior to the telephone conference.
To participate in the telephone conference, please call:
SE: +46 8 519 993 68
UK: +44 203 364 5372
US: +1 855 269 2606
To view the presentation, please visit:
http://event.onlineseminarsolutions.com/r.htm?e=820454&s=1&k=B8957F15C9E09FDF1676B8D98A3D9686
About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
For more information please contact
Media relations
Oskar Bosson
Head of Communications
T: +46 70 410 71 80
oskar.bosson@sobi.com
Investor relations
Jörgen Winroth
Vice President, Head of Investor Relations
T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
jorgen.winroth@sobi.com
Help employers find you! Check out all the jobs and post your resume.
